Highlights Fortress Biotech, Inc. Nasdaq

Equities

FBIOP

US34960Q2084

Market Closed - Nasdaq Other stock markets 15:58:22 2024-06-07 EDT			5-day change	1st Jan Change
16.73 ^USD	+1.70%		+5.42%	+40.94%

05-15	Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-15	Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M	05-15	MT
Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex	05-14	MT
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation	05-14	CI
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q3 Revenue $34.8M	11-14	MT
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)	23-10-20	CI
Reverse Split: 1 of 15	23-10-09	FA
Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q2 Revenue $17.4M	23-08-14	MT
Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $12.4M	23-05-15	MT
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights	23-03-29	AQ
Fortress Biotech Unit Expands Gout Drug License Deal With Fuji Yakuhin to Include New Markets	22-12-14	MT
Urica Therapeutics, Inc Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa	22-12-14	CI
Fortress Biotech Swings to Q3 Non-GAAP Loss, Revenue Drops	22-11-14	MT
Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q3 Revenue $16.5M	22-11-14	MT
Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q3 Revenue $16.1M	22-11-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fortress Biotech, Inc. Nasdaq

Equities

FBIOP

US34960Q2084

Highlights

Filters